These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 24731681)

  • 1. Acute hyperammonemic encephalopathy in a non-cirrhotic patient with hepatocellular carcinoma reversed by arginine therapy.
    Shinde SS; Sharma P; Davis MP
    J Pain Symptom Manage; 2014 Apr; 47(4):e5-7. PubMed ID: 24731681
    [No Abstract]   [Full Text] [Related]  

  • 2. Postchemotherapy hyperammonemic encephalopathy emulating ornithine transcarbamoylase (OTC) deficiency.
    Chan JS; Harding CO; Blanke CD
    South Med J; 2008 May; 101(5):543-5. PubMed ID: 18414167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Proposed Physiopathological Pathway to Hyperammonemic Encephalopathy in a Non-Cirrhotic Patient with Fibrolamellar Hepatocellular Carcinoma without Ornithine Transcarbamylase (OTC) Mutation.
    Surjan RC; Dos Santos ES; Basseres T; Makdissi FF; Machado MA
    Am J Case Rep; 2017 Mar; 18():234-241. PubMed ID: 28270654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Valproate-induced hyperammonemic encephalopathy].
    Diaz-Rangel M; Grande-Martin A; Monsalve-Naharro JA; Domingo-Chiva E; Cuesta-Montero P; Lopez-Perez A
    Rev Neurol; 2017 Dec; 65(12):574-575. PubMed ID: 29235622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sunitinib-induced hyperammonemic encephalopathy in gastrointestinal stromal tumors.
    Lee NR; Yhim HY; Yim CY; Kwak JY; Song EK
    Ann Pharmacother; 2011 Oct; 45(10):e56. PubMed ID: 21954449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imbalance and gait disturbance from tyrosine kinase inhibition in hepatocellular cancer.
    Miksad RA; Lai KC; Stein MC; Healy ME; Rojas R; Krajewski KM; Zhu AX
    J Gastrointest Cancer; 2009; 40(3-4):119-22. PubMed ID: 19894033
    [No Abstract]   [Full Text] [Related]  

  • 7. Hyperammonemic Encephalopathy Associated With Fibrolamellar Hepatocellular Carcinoma: Case Report, Literature Review, and Proposed Treatment Algorithm.
    Chapuy CI; Sahai I; Sharma R; Zhu AX; Kozyreva ON
    Oncologist; 2016 Apr; 21(4):514-20. PubMed ID: 26975868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A case of metastatic colorectal cancer with hyperammonemic encephalopathy induced by 5-FU in a patient continuously treated with XELOX therapy].
    Nakano E; Kuroki M; Kanno N; Matsumura Y; Miura A; Kikuchi Y; Hirakawa H
    Gan To Kagaku Ryoho; 2013 Dec; 40(13):2581-4. PubMed ID: 24335375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of Paraneoplastic Hyperammonemia in Fibrolamellar Hepatocellular Carcinoma With Oral Sodium Phenylbutyrate.
    Bender HU; Staudigl M; Schmid I; Führer M
    J Pain Symptom Manage; 2015 Jun; 49(6):e8-10. PubMed ID: 25891666
    [No Abstract]   [Full Text] [Related]  

  • 10. Sunitinib in hepatocellular carcinoma: redefining appropriate dosing, schedule, and activity end points.
    Faivre SJ; Bouattour M; Dreyer C; Raymond E
    J Clin Oncol; 2009 Dec; 27(35):e248-50; author reply e251-2. PubMed ID: 19901099
    [No Abstract]   [Full Text] [Related]  

  • 11. Hypercalcemic encephalopathy in a patient with hepatocellular carcinoma.
    Tudela P; Soldevila B; Mòdol JM; Domènech E
    Dig Dis Sci; 2007 Nov; 52(11):3296-7. PubMed ID: 17429730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of sunitinib in advanced hepatocellular carcinoma.
    Barone C; Basso M; Biolato M; Pompili M; Rufini V; Miele L; Basso M; De Gaetano AM; Castaldi P; Iaculli A; Leccisotti L; Riccardi L; Grieco A
    Dig Liver Dis; 2013 Aug; 45(8):692-8. PubMed ID: 23410734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apatinib-induced hyperammonemic encephalopathy.
    Liu Y; Chen X; Gao X; Chen JX; Chen J
    J Oncol Pharm Pract; 2020 Mar; 26(2):465-470. PubMed ID: 31068089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Out of control: hepatitis B reactivation by transarterial treatment of hepatocellular carcinoma.
    von Weizsäcker F; Blum HE
    J Hepatol; 2004 Sep; 41(3):482-4. PubMed ID: 15336452
    [No Abstract]   [Full Text] [Related]  

  • 15. Hyperammonemic encephalopathy: a rare presentation of fibrolamellar hepatocellular carcinoma.
    Sethi S; Tageja N; Singh J; Arabi H; Dave M; Badheka A; Revankar S
    Am J Med Sci; 2009 Dec; 338(6):522-4. PubMed ID: 20010160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib.
    Alexandrescu DT; McClure R; Farzanmehr H; Dasanu CA
    J Clin Oncol; 2008 Aug; 26(24):4047-8. PubMed ID: 18711201
    [No Abstract]   [Full Text] [Related]  

  • 17. Transient sunitinib-induced coma in a patient with fibromyxoid sarcoma.
    Arnaud L; Schartz NE; Bousquet G; Sarandi F; Verola O; Madelaine I; Kerob D; Lebbe C
    J Clin Oncol; 2008 Mar; 26(9):1569-71. PubMed ID: 18349416
    [No Abstract]   [Full Text] [Related]  

  • 18. Acute Onset Hyperammonemic Encephalopathy Related to Fibrolamellar Carcinoma: Another One Bites the Dust.
    Surjan RCT; Silveira SP; Pinheiro JLS; Pinheiro PHS; Barros MFA; Soares SRP
    Am J Med Sci; 2020 Apr; 359(4):242-244. PubMed ID: 32014302
    [No Abstract]   [Full Text] [Related]  

  • 19. Hyperammonemic Encephalopathy Exacerbated by Parenteral Nutrition in Fibrolamellar Hepatocellular Carcinoma.
    Shah PA; Cho J; Albitar HAH; Pajot G; Liu M; Ravi K
    Am J Med; 2020 Dec; 133(12):e745-e746. PubMed ID: 32739410
    [No Abstract]   [Full Text] [Related]  

  • 20. Acute hepatitis in a patient with cirrhosis and hepatocellular carcinoma treated with sorafenib.
    Llanos L; Bellot P; Zapater P; Pérez-Mateo M; Such J
    Am J Gastroenterol; 2009 Jan; 104(1):257-8. PubMed ID: 19098892
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.